Unlocking the Mystery of cGMP Peptides: Key Considerations for GMP Compliance in Peptide Drug Quality Control

Apr 11, 2024

The Emergence of Targeted Peptide Drugs

Peptides are short chains of amino acids, typically consisting of fewer than 40 amino acid residues, and are crucial in biological processes such as signaling, enzyme function, and immune response ^[1-2]. They can be designed to target specific receptors or enzymes in the body to regulate biological processes or disrupt disease pathways. Peptide drugs are gaining attention due to their high specificity, low toxicity, and relatively few side effects compared to traditional small molecule drugs ^[3]. Some well-known peptide drugs on the market include:

• Insulin: While not a targeted therapy in the modern sense, insulin was one of the first biologics to demonstrate the power of peptide-based treatments. It specifically binds to insulin receptors on cells, allowing glucose uptake and helping to maintain blood glucose homeostasis ^[4].
• GLP-1 Receptor Agonists (Liraglutide, Exenatide): These drugs mimic the incretin hormone GLP-1, which is naturally released in response to food intake and targets receptors in the pancreas to stimulate insulin release. By targeting the GLP-1 receptor, these drugs improve blood sugar control in a glucose-dependent manner, reducing the risk of hypoglycemia ^[5].

The Role of GMP in peptide drug development

GMP stands for Good Manufacturing Practice, and it is a set of quality control guidelines and regulations that govern the manufacturing, testing, and quality assurance of pharmaceutical products. GMP ensures that drugs are consistently produced and controlled by quality standards appropriate for their intended use. These standards cover all aspects of the production process, including facility cleanliness, personnel training, equipment maintenance, record-keeping, and product testing. Adhering to GMP regulations helps ensure the safety, quality, and efficacy of pharmaceutical products, and is a critical part of the regulatory framework for the pharmaceutical industry. Compliance with GMP standards is typically enforced by regulatory agencies such as the FDA in the United States ^[6] and the EMA in the European Union ^[7].

GMP compliant production is typically required for peptide drug when moving to clinical trials and ultimately to commercial production. Peptide drug release must pass identity, purity, potency, sterility tests and have stability studies to support the shelf-life and storage condition. However, GMP requirements for peptide drug development are dependent on the drug type, use, and production scale, for example:

• Neoantigen Peptides: Require appropriate GMP due to personalized, small-scale production for clinical use.
• GLP-1 Receptor Agonists: GMP starts typically for Phase I trials, with larger-scale production.
• Other Peptide drugs: GMP generally begins from Phase I clinical trials, scale varies by market demand.

Key Considerations for GMP Compliance in Peptide Drug Quality Control

There are several key considerations for controlling the quality of peptide drugs ^[4-7]:

1. Manufacturing Processes: Implementing well-defined and validated manufacturing processes is crucial to ensure consistency and quality in the production of peptide drugs. This includes controlling parameters such as temperature, pH, and reaction times during synthesis.
2. Raw Material Control: Ensuring the quality of raw materials, including amino acids and reagents, is essential for the production of high-quality peptide drugs. Robust supplier qualification and material testing protocols should be in place.
3. Equipment and Facility Maintenance: Regular maintenance and calibration of equipment used in peptide synthesis, purification, and analysis is essential to ensure accuracy and reproducibility. Facility cleanliness and environmental controls are also critical.
4. Quality Control Testing: Implementing comprehensive quality control testing throughout the manufacturing process, including in-process testing and final product testing, is necessary to verify the identity, purity, and potency of the peptide drug.
5. Documentation and Record-Keeping: Maintaining thorough documentation of all manufacturing and quality control activities is essential for GMP compliance. This includes batch records, testing results, and deviations from established procedures.
6. Personnel Training and Qualification: Providing ongoing training and qualification programs for personnel involved in peptide drug manufacturing is crucial to ensure that they understand and adhere to GMP requirements.
7. Stability Testing: Conducting stability testing to assess the shelf-life and storage conditions of the peptide drug is important to ensure that the product remains safe and effective throughout its intended shelf life.

By effectively implementing these measures and adhering to GMP standards, the quality of peptide drugs can be controlled and maintained at high standards.

Discover GenScript's Enhanced cGMP Peptide Production

Production Facility

cGMP manufacturing opened 2023

One stop service, provide API manufacturing process development to regulatory compliance for IND application

Clean suite with Grade A isolator for sterile peptide

Sterilization filtration and aseptic filling for neoantigen

Process development and scale-up competence

Delivers up to 48 personalized neoantigen sequences/patient/batch, enabling rapid manufacturing, QC, and release.

Complex sequences and peptide modifications adapted to large scale production, including cyclic peptides and peptide-drug conjugates.

QA/QC & Documentation

Traceable and comprehensive batch production records

Identity, purity, bioburden, endotoxin, etc. for releasing specification

Material supplier management

Analytical method development, verification and validation

Long-term stability study, accelerated stability study and stress condition studies compliance with ICH guidance

Phase-appropriate GMP implemented and documented

TSE/BSE statement

Download The Free PDF

Visit cGMP Peptide Synthesis | GenScript for more info.

Reference

• 1. Forbes J et al., Biochemistry, Peptide. PMID: 32965931 (2023).
• 2. Apostolopoulos, et al. (2021). A Global Review on Short Peptides: Frontiers and Perspectives. Molecules 2021, 26(2), 430; https://doi.org/10.3390/molecules26020430.
• 3. Muttenthaler, M., King, et al. (2021). Trends in peptide drug discovery. Nat Rev Drug Discov 20, 309–325. https://doi.org/10.1038/s41573-020-00135-8
• 4. Li, M., Chi, X., Wang, Y. et al. (2022). Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Sig Transduct Target Ther 7, 216. https://doi.org/10.1038/s41392-022-01073-0
• 5. Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic advances in endocrinology and metabolism, 12, 2042018821997320. https://doi.org/10.1177/2042018821997320
• 6.〈1503〉 QUALITY ATTRIBUTES OF SYNTHETIC PEPTIDE DRUG SUBSTANCES, USP
• 7. Guideline on the Development and Manufacture of Synthetic Peptides EMA/CHMP/CVMP/QWP/387541/2023